Mucositis in patients with hematologic malignancies: An overview

Haematologica

Volumn 92, Issue 2, 2007, Pages

  Niscola, Pasquale ^a,c   Romani, Claudio ^b   Cupelli, Luca ^a   Scaramucci, Laura ^a   Tendas, Andrea ^a   Dentamaro, Teresa ^a   Amadori, Sergio ^a   De Fabritiis, Paolo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Ospedale Oncologico A Businco   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

Author keywords

Graft versus host disease; Hematologic malignancies; Hematopoietic stem cell transplantation; Mucositis; Pain

Indexed keywords

ANALGESIC AGENT; ANTIINFECTIVE AGENT; BLEOMYCIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IDARUBICIN; IRINOTECAN; LACTOFERRIN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PALIFERMIN; PILOCARPINE; PREDNISONE; RITUXIMAB; STEROID; TIOGUANINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG MECHANISM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PARENTERAL NUTRITION; PATHOGENESIS; PROPHYLAXIS; RISK FACTOR; BLOOD DISEASE; DRUG EFFECT; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; MALE; METHODOLOGY; MUCOSA; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MUCOSITIS; MUCOUS MEMBRANE; RISK FACTORS; TRANSPLANTATION CONDITIONING;

EID: 33947492500     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10232     Document Type: Article

References (93)

1. Blijlevens NMA, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 2000;25:1269-78.
2. Sonis ST. The pathobiology of mucositis. Nat Rev 2004;30:277.
3. Niscola P, Arcuri E, Giovannini M, Scaramucci L, Romani C, Palombi F, et al. Pain syndromes in haematological malignancies: an overview. Hematol J 2004;5:293-303.
4. Brown CG, Wingard J. Clinical consequences of oral mucositis. Semin Oncol Nurs 2004;20:16-21.
5. O'Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: recent developments. Hematology (Am Soc Hematol Educ Program) 2003;438-72.
6. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19:2201-5.
7. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100 Suppl 9:1995-2025.
8. Micozzi A, Cartoni C, Monaco M, Martino P, Zittoun R, Mandelli F. High incidence of infectious gastrointestinal complications observed in patients with acute myeloid leukemia receiving intensive chemotherapy for first induction of remission. Support Care Cancer 1996;4:294-7.
9. Goldberg J, Jacobsohn DA, Zahurak ML, Vogelsang GB. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:101-7.
10. Ross WA, Couriel D. Colonic graft-versus-host disease. Curr Opin Gastroenterol 2005;21:64-9.
11. Stoopler ET. Oral herpetic infections (HSV 1-8). Dent Clin North Am 2005; 49:15-29.
12. Niscola P, Scaramucci L, Giovannini M, Anghel G, Romani C, Palombi F, et al. Palliative care in malignant hematology: an overview. Haema 2005;8: 297-315.
13. Christopher A. Squier, Mary J. Kremer. Biology of oral mucosa and esophagus. J Nad Cancer Inst Monographs 2001;29:7-15.
14. Seare NJ, Playford RJ. Growth factors and gut function. Proc Nutr Soc 1998; 57:403-8.
15. Miaskowski C. Biology of Mucosal Pain. J Natl Cancer Inst Monographs 2001;29:37-40.
16. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 2003;39:91-100.
17. Evans WE, McLeod HL. Pharmacogenomics; drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-49.
18. Robien K, Schubert MM, Chay T, Bigler J, Storb R, Yasui Y, et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37:799-800.
19. Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 2005;15:801-15.
20. Martelli M, Rigacci L, Nassi L, Finolezzi E, Bizzoni L, Alterini R, et al. Rituximab plus CHOP- 14 for the treatment of patients with aggressive non-Hodgkin's lymphoma. Haematologica 2005;90 Suppl 3:270.
21. Milone G, Di Raimondo F, Gioi FL, Palumbo GA, Manenti GO, Pafumi M, et al. Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas. Leuk Lymphoma 2002; 43:2319-24.
22. Mazza P, Zinzani PL, Martelli M, Fiacchini M, Bocchia M, Pileri S, et al. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. Leuk Lymphoma 1995;16:457-63.
23. Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005; 23:9208-18.
24. Friedenberg WR, Miller HJ, Marx JJ Jr, Schloesser XL, Reding DJ, Mazza JJ, et al. The treatment of older adult patients with acute myeloid leukemia by triple infusion chemothera-py. Am J Clin Oncol 1995;18:105-10.
25. Pea F, Russo D, Michieli M, Damiani D, Fanin R, Michelutti A, et al. Disposition of liposomal daunorubicin during co treatment with cytarabine in patients with leukaemia. Clin Pharmacokinetics 2003; 42:851-62.
26. Ferrara F, Palmieri S, Pocali B, Pollio F, Viola A, Annunziata S, et al. De novo acute myeloid leukemia with multi-lineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol 2002;68:203-9.
27. Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol 2003;82:231-5.
28. Girmenia C, Lo Coco F, Breccia M, Latagliata R, Spadea A, D'Andrea M, et al. Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. Leukemia 2003;17:925-30.
29. Testi AM, Biondi A, Lo Coco F, Moleti ML, Giona F, Vignetti M, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005;106:447-53.
30. Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16: 1627-36.
31. Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med 2004; 34 Suppl 1:4-9.
32. Bolwell BJ, Kalaycio M, Sobecks R, Andresen S, Kuczkowski E, Bernhard L, et al. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 2002;30:587-91.
33. Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000; 110:292-9.
34. Martino M, Morabito F, Console G, Irrera G, Messina G, Pucci G, et al. Differences in transplant-related complications between hematologic malignancies and solid tumors receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Tumori 2003;89:385-90.
35. Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 2004;34:581-7.
36. Ferrara F, Palmieri S, De Simone M, Sagristani M, Viola A, Pocali B, et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 2005;128:234-41.
37. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99:731-5.
38. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052-7.
39. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993; 72:1612-7.
40. Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004;22:1268-75.
41. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate-and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005;11: 383-8.
42. Johansson J-E, Brune M., Ekman T. The gut mucosa barrier is preserved during allogeneic, haematopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transplant 2001;28:737-42.
43. Ross WA. Treatment of gastrointestinal acute graft-versus-host disease. Curr Treat Options Gastroenterol 2005; 8:249-58.
44. Dominguez Reyes A, Aznar Martin T, Barberia Leache E, Cabrera Suarez E. Oral manifestations of graft versus host disease. Med Oral 2003;8:361-5.
45. McGuire DB, Yeager KA, Dudley WN, Peterson DE, Owen DC, Lin LS, et al. Acute oral pain and mucositis in bone marrow transplant and leukemia patients: data from a pilot study. Cancer Nurs 1998;21:385-93.
46. McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 1993; 20:1493-502.
47. Sonis ST. The biologic role for nuclear factor-kB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 2002;13:380-9.
48. Bowen JM, Gibson RJ, Cummins AG, Keefe DM. Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 2006; 14:713-31.
49. Johansson JE, Ekman T. Gastro-intestinal toxicity related to bone marrow transplantation: disruption of the intestinal barrier precedes clinical findings. Bone Marrow Transplant 1997; 19:921-5.
50. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997;15:2254-61.
51. Gorschluter M, Marklein G, Hofling K, Clarenbach R, Baumgartner S, Hahn C, et al. Abdominal infections in patients with acute leukaemia: a prospective study applying ultrasonography and microbiology. Br J Haematol 2002; 117:351-8.
52. Radu B, Allez M, Gornet JM, Lemann M, Socie G, Gluckman E, et al. Chronic diarrhoea after allogeneic bone marrow transplantation. Gut 2005;54:161-74.
53. Cox GJ, Matsui SM, Lo RS, Hinds M, Bowden RA, Hackman RC, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 1994; 107:1398-407.
54. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354:1813-26.
55. Horwitz ME, Sullivan KM. Chronic graft-versus-host disease. Blood Rev 2006;20:15-27.
56. Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW. Conditioning-related toxicity and acute graft-versus-host-disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant 1991; 7:193.
57. Imanguli MM, Pavletic SZ, Guadagnini JP, Brahim JS, Atkinson JC. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101: 175-83.
58. WCCNR: Assessing stomatitis: refinement of the Western Consortium for Cancer Nursing Research (WCCNR) stomatitis staging system. Can Oncol Nurs J 1998;8:160-5.
59. McGuire DB, Peterson DE, Muller S, Owen DC, Slemmons MF, Schubert MM. The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients. Cancer Invest 2002;20:893-903.
60. Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR, et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 2003;98:406-12.
61. Niscola P, Scaramucci L, Romani C, Giovannini M, Maurillo L, Del Poeta G, et al. Opioids in pain management of blood-related malignancies. Ann Ann Hematol 2006;85:489-501.
62. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100 Suppl 9: 2026-46.
63. Daniel BT, Damato KL, Johnson J. Educational issues in oral care. Semin Oncol Nurs 2004;20:48-52.
64. Migliorati CA, Oberle-Edwards L, Schubert M. The role of alternative and natural agents, cryotherapy, and/or laser for management of alimentary mucositis. Support Care Cancer 2006; 14:533-40.
65. Wright J, Feld R, Knox J. Chemotherapy-induced oral mucositis: new approaches to prevention and management. Expert Opin Drug Saf 2005; 4:193-200.
66. Lovenich H, Schutt-Gerowitt H, Keulertz C, Waldschmidt D, Bethe U, Sohngen D, et al. Failure of anti-infective mouth rinses and concomitant antibiotic prophylaxis to decrease oral mucosal colonization in autologous stem cell transplantation. Bone Marrow Transplant 2005;35: 997-1001.
67. van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, van Dijk-Overtoom ML, et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Ann Hematol 2001; 80:150-4.
68. Lockhart PB, Brennan MT, Kent ML, Packman CH, Norton HJ, Fox PC, et al. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplant 2005;35:713-20.
69. Elad S, Ackerstein A, Bitan M, Shapira MY, Resnick I, Cesundheit B, et al. Prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone Matrow Transplant 2006; 37:757-62.
70. Pytlik R. Standardized parenteral alanyn-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind placebo controlled study. Bone Marrow Trans 2002;20: 953-61.
71. Sironi M, Milanese C, Vecchi A, Polenzani L, Guglielmotti A, Coletta I, et al. Benzydamine inhibits the release of tumor necrosis factor-alpha and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells. Int J Clin Lab Res 1997;27:118-22.
72. Yuen KY, Woo PC, Tai JW, Lie AK, Luk J, Liang R. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica 2001; 86:554-5.
73. Capelli D, Santini G, De Souza C, Poloni A, Marino G, Montanari M, et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 2000;110:300-7.
74. Lalla RV, Schubert MM, Bensadoun RJ, Keefe D. Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer 2006;14:558-65.
75. Stiff PJ. Oral mucositis therapy comes of age. J Support Oncol 2005; Suppl 2:73-5.
76. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351: 2590-8.
77. Braun S, Hanselmann C, Gassmann MG, auf dem Keller U, Born-Berclaz C, Chan K, et al. Nrf2 transcription factor, a novel target of keratinocyte growth factor action, which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 2002;22:5492-505.
78. von Bültzingslöwen I, Brennan MT, Spijkervet FKL, Logan R, Stringer A, Raber-Durlacher JE, et al. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Canc 2006; 14:519-27.
79. Hofmeister CC, Stiff PJ. Mucosal protection by cytokines. Curr Hematol Rep 2005;4:446-53.
80. Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 2002;29:373-7.
81. Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD Drugs 2002;62:879-89.
82. Ross WA. Treatment of gastrointestinal acute graft-versus-host disease. Curr Treat Options Gastroenterol 2005;8:249-58.
83. Castilla C, Pérez-Simón JA, Sánchez-Guijo F, Caballero D, Cañizo MC, Diez-Campelo M et al. Topic therapy on gut acute graft-versus-host disease (GVHD). Hematol J 2004;3 Suppl 2: 160.
84. Stadler M, Starke O, Reuter CWM, Eckardt B, Hertenstein B. Highly effective topical tacrolimus treatment in several oral chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Haematol J 2004; 3 Suppl 2:158.
85. Stephanie J Lee. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005; 105: 4200-6.
86. Schmid I, Schmitt M, Streiter M, Meilbeck R, Albert MH, Reinhardt D, et al. Parenteral nutrition is not superior to replacement fluid therapy for the supportive treatment of chemotherapy induced oral mucositis in children. Eur J Cancer 2006;42:205-11.
87. Epstein JB, Schubert MM. Managing pain in mucositis. Semin Oncol Nurs 2004;20:30-7.
88. Cerchietti LC, Navigante AH, Korte MW, Cohen AM, Quiroga PN, Villaamil EC, et al. Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain 2003;105:265-73.
89. Chapman CR, Donaldson GW, Jacobson RC, Hautman B. Differences among patients in opioid self-administration during bone marrow transplantation. Pain 1997;71:213-23.
90. Strupp C, Sudhoff T, Germing U, Hunerliturkoglu A, Schneider P, Niederste-Hollenberg A, et al. Transdermal fentanyl during high-dose chemotherapy and autologous stem cell support. Oncol Rep 2000;7:659-61.
91. Demarosi F, Lodi G, Soligo D, Sardella A, Volpe AD, Carrassi A et al. Transdermal fentanyl in HSCT patients: an open trial using transdermal fentanyl for the treatment of oral mucositis pain. Bone marrow Transplant 2004;33:1247-51.
92. Kim JG, Sohn SK, Kim DH, Baek JH, Chae YS, Bae NY, et al. Effectiveness of transdermal fentanyl patch for treatment of acute pain due to oral mucositis in patients receiving stem cell transplantation. Transplant Proc 2005; 37:4488-91.
93. Anthony L, Bowen J, Garden A, Hewson I, Sonis S. New thoughts on the pathobiology of regimen-related mucosal injury. Support Care Cancer 2006;14:516-8.